Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Sales (2020 - 2023)

Gain Therapeutics has reported Return on Sales over the past 4 years, most recently at 403.54% for Q4 2023.

  • Quarterly results put Return on Sales at 403.54% for Q4 2023, down 40177.0% from a year ago — trailing twelve months through Dec 2023 was 403.54% (down 40177.0% YoY), and the annual figure for FY2023 was 403.54%, down 40177.0%.
  • Return on Sales for Q4 2023 was 403.54% at Gain Therapeutics, down from 88.37% in the prior quarter.
  • Over the last five years, Return on Sales for GANX hit a ceiling of 84.34% in Q4 2021 and a floor of 465.07% in Q1 2021.
  • Median Return on Sales over the past 4 years was 86.51% (2023), compared with a mean of 120.11%.
  • Biggest five-year swings in Return on Sales: surged 39235bps in 2022 and later plummeted -40177bps in 2023.
  • Gain Therapeutics' Return on Sales stood at 181.17% in 2020, then soared by 147bps to 84.34% in 2021, then plummeted by -102bps to 1.78% in 2022, then plummeted by -22603bps to 403.54% in 2023.
  • The last three reported values for Return on Sales were 403.54% (Q4 2023), 88.37% (Q3 2023), and 85.47% (Q2 2023) per Business Quant data.